...
首页> 外文期刊>Archives of Pharmacal Research >Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS
【24h】

Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS

机译:使用LC-MS / MS通过凝胶辅助消化和无标记定量方法对乳腺癌组织进行蛋白质组学分析以鉴定候选生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

This study presents a proteomic method that differentiates between matched normal and breast tumor tissues from ductal carcinoma in situ (DCIS) and invasive carcinoma from Korean women, to identify biomarker candidates and to understand pathogenesis of breast cancer in protein level. Proteins from tissues obtained by biopsy were extracted by RIPA buffer, digested by the gel-assisted method, and analyzed by nano-UPLC-MS/MS. From proteomic analysis based on label-free quantitation strategy, a non-redundant list of 298 proteins was identified from the normal and tumor tissues, and 244 proteins were quantified using IDEAL-Q software. Hierarchical clustering analysis showed two patterns classified as two groups, invasive carcinoma and DCIS, suggesting a difference between two carcinoma at the protein expression level as expected. Differentially expressed proteins in tumor tissues compared to the corresponding normal tissues were related to three biological pathways: antigen-processing and presentation, glycolysis/gluconeogenesis, and complement and coagulation cascades. Among them, the up-regulation of calreticulin (CRT) and protein disulfide isomerase A3 (PDIA3) was confirmed by Western blot analysis. In conclusion, this study showed the possibility of identifying biomarker candidates for breast cancer using tissues and might help to understand the pathophysiology of this cancer at the protein level.
机译:这项研究提出了一种蛋白质组学方法,可以区分来自导管原位癌(DCIS)的正常组织和乳腺癌组织以及来自韩国女性的浸润性癌,以鉴定候选生物标志物并从蛋白水平了解乳腺癌的发病机理。通过RIPA缓冲液提取通过活检获得的组织中的蛋白质,通过凝胶辅助方法进行消化,然后通过nano-UPLC-MS / MS进行分析。通过基于无标记定量策略的蛋白质组学分析,从正常和肿瘤组织中鉴定出298种蛋白质的非冗余列表,并使用IDEAL-Q软件对244种蛋白质进行了定量。层次聚类分析显示出两种模式分为两组:浸润性癌和DCIS,这表明两种癌在蛋白表达水平上存在差异。与相应的正常组织相比,肿瘤组织中差异表达的蛋白质与三个生物学途径有关:抗原加工和呈递,糖酵解/糖异生以及补体和凝血级联反应。其中,通过蛋白质印迹分析证实了钙网蛋白(CRT)和蛋白质二硫键异构酶A3(PDIA3)的上调。总而言之,这项研究显示了使用组织识别乳腺癌生物标志物候选物的可能性,并且可能有助于从蛋白水平理解该癌症的病理生理学。

著录项

  • 来源
    《Archives of Pharmacal Research》 |2012年第10期|p.1839-1847|共9页
  • 作者单位

    Department of Molecular Medicine, Cell and Matrix Biology Research Institute, School of Medicine, Kyungpook National University, Daegu, 700-422, Korea;

    Department of Molecular Medicine, Cell and Matrix Biology Research Institute, School of Medicine, Kyungpook National University, Daegu, 700-422, Korea;

    Department of Molecular Medicine, Cell and Matrix Biology Research Institute, School of Medicine, Kyungpook National University, Daegu, 700-422, Korea;

    College of Pharmacy, Chungnam National University, Daejeon, 305-764, Korea;

    College of Pharmacy, Yeungnam University, Kyoungbuk, 712-749, Korea;

    Department of Oncology, Kyungpook National University Hospital, Daegu, 700-422, Korea;

    Department of Pathology, Kyungpook National University Hospital, Daegu, 700-422, Korea;

    Department of Surgery, Kyungpook National University Hospital, Daegu, 700-422, Korea;

    Department of Molecular Medicine, Cell and;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Breast cancer; Ductal carcinoma in situ; Biomarker candidates; Proteomics; LCMS/MS;

    机译:乳腺癌;原位管癌;候选生物标志物;蛋白质组学;LCMS / MS;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号